文献速递肿瘤 PET/CT

18F-氟甲胆碱与68Ga-PSMA-11在前列腺癌生化复发PET/CT中的前瞻性头对头比较

A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT.
PubMed 文献 · Clin Nucl Med · 2019-01-01

该前瞻性研究纳入58例根治性治疗后生化复发的前列腺癌患者,在平均9.4天时间窗内分别行18F-氟甲胆碱与68Ga-PSMA-11 PET/CT,独立进行基于患者、区域和病灶的视觉分析。总体检出率两者无显著差异(79.3% vs 82.8%,P=0.64),18F-氟甲胆碱在局部复发检出上显著更高(37.9% vs 27.6%,P=0.03),而68Ga-PSMA-11在远处转移检出上数值更高但未报告统计学比较。结论认为18F-氟甲胆碱优势在于检测毗邻膀胱的局部可治愈病灶,远处转移检测与68Ga-PSMA-11几乎等效。

要点

  • 总体复发检出率18F-氟甲胆碱79.3%与68Ga-PSMA-11 82.8%无显著差异(P=0.64)。
  • 局部复发检出18F-氟甲胆碱37.9%显著高于68Ga-PSMA-11 27.6%(P=0.03)。
  • 18F-氟甲胆碱可检出毗邻膀胱的局部病灶,而68Ga-PSMA-11因膀胱放射性积聚而失败。

核心结论

  • 18F-氟甲胆碱优势在于检测毗邻膀胱的局部可治愈病灶,而68Ga-PSMA-11因膀胱放射性积聚而失败。
  • 18F-氟甲胆碱在检测前列腺癌复发远处转移方面与68Ga-PSMA-11几乎等效。

研究设计与样本

  • 前瞻性头对头比较研究,纳入58例根治性原发治疗后生化复发的前列腺癌患者。
  • 两次扫描在平均9.4天的时间窗内完成,均在同一医疗科室使用相同扫描仪进行。
  • 所有扫描独立进行基于患者、区域和病灶的视觉分析。

主要发现

  • 前列腺癌复发总体检出率18F-氟甲胆碱为79.3%,68Ga-PSMA-11为82.8%(P=0.64)。
  • 局部复发检出率18F-氟甲胆碱为37.9%,68Ga-PSMA-11为27.6%(P=0.03)。
  • 盆腔局部淋巴结复发检出率18F-氟甲胆碱为46.6%,68Ga-PSMA-11为50%。
  • 盆腔外淋巴结转移检出率18F-氟甲胆碱为41.4%,68Ga-PSMA-11为51.7%。
  • 骨转移检出率18F-氟甲胆碱为25.9%,68Ga-PSMA-11为36.2%。

关键数值与推荐

  • 病灶分析显示盆腔局部淋巴结所见一致率为39.7%,盆腔外淋巴结为22.4%,骨转移为13.8%。

临床怎么用

  • 对于生化复发患者,18F-氟甲胆碱可优先用于评估毗邻膀胱的局部可治愈病灶。
  • 68Ga-PSMA-11在检测远处转移方面与18F-氟甲胆碱几乎等效,但需注意膀胱放射性积聚可能掩盖局部病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: One of the major challenges for all imaging modalities is accurate detection of prostate cancer (PCa) recurrence. Beyond the established Ga-PSMA, a novel promising PET tracer in PCa imaging is F-fluciclovine. For evaluating the advantages and disadvantages and the comparability, we conducted a prospective head-to-head comparison on F-fluciclovine and Ga-PSMA-11 in patients with biochemical recurrence of PCa. METHODS: 58 patients with biochemical recurrence of PCa after definitive primary therapy were included. Both scans were performed within a time window of mean 9.4 days. All scans were visually analyzed independently on a patient-, region- and lesion-based analysis. All the examinations were performed in the same medical department using identical scanners at any time. RESULTS: The overall detection rate for PCa recurrence was 79.3% in F-fluciclovine and 82.8% in Ga-PSMA-11 (P = 0.64). Local recurrence was detected in 37.9% on F-fluciclovine and in 27.6% on Ga-PSMA-11 (P = 0.03). Local pelvic lymph node recurrence was detected on F-fluciclovine versus Ga-PSMA-11 in 46.6% versus 50%, in extrapelvic lymph node metastases in 41.4% versus 51.7% and in bone metastases in 25.9% versus 36.2%. Lesion-based analysis showed identical findings in local pelvic lymph nodes in 39.7%, in extrapelvic lymph nodes in 22.4%, and in bone metastases in 13.8%. CONCLUSIONS: The advantage of F-fluciclovine is detecting curable localized disease in close anatomical relation to the urinary bladder, whereas Ga-PSMA-11 fails because of accumulation of activity in the urinary bladder. F-fluciclovine is almost equivalent to Ga-PSMA-11 in detecting distant metastases of PCa recurrence.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pernthaler B, Kulnik R, Gstettner C, et al. A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT. Clin Nucl Med. 2019. PMID: 31283605. doi:10.1097/RLU.0000000000002703

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。